| Literature DB >> 33581425 |
Ruby Cy Lin1, Jessica C Sacher2, Pieter-Jan Ceyssens3, Jan Zheng4, Ali Khalid5, Jonathan R Iredell6.
Abstract
After a century of use in human infection, the preparation and administration of therapeutic bacteriophages (phages) still relies on ad hoc partnerships of researchers, biotech companies, clinicians and regulators. There is a clear need to improve the reproducibility, safety and speed of the provision of suitable phages. Here we discuss the specific characteristics and challenges of a sustainable phage biobank and, as we build a national consortium aimed at delivering phage therapeutics, suggest a roadmap toward national biobanking and phage therapy initiatives using the Australian context as a model. CrownEntities:
Year: 2021 PMID: 33581425 DOI: 10.1016/j.copbio.2020.12.018
Source DB: PubMed Journal: Curr Opin Biotechnol ISSN: 0958-1669 Impact factor: 9.740